As health officials grapple with a fast-moving outbreak of the Bundibugyo ebolavirus in the Democratic Republic | Officials are planning to study Mapp Biopharmaceutical’s MBP134 and Gilead Sciences’ remdesivir, which gained prominence during the COVID-19 pandemic, against the Bundibugyo ebolavirus.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
A clinical trial testing two drugs against the Bundibugyo ebolavirus, which is driving a fast-moving outbreak in Central Africa,…
The adaptive study will test two experimental therapies as the largest recorded Bundibugyo Ebola outbreak infects nearly 1,600…
As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. | As…
Clinical trials for treatments against Ebola Bundibugyo virus are ‘in a strong position’ to be launched quickly in the Democratic…
Clinical trials for treatments against Ebola Bundibugyo virus are ‘in a strong position’ to be launched quickly in the Democratic…
The WHO advisors also recommended evaluating combination therapy using a monoclonal antibody together with remdesivir.
